Rivoglitazone, a new oral therapy for the treatment of type 2 diabetes

Current Opinion in Investigational Drugs

Volumn 8, Issue 4, 2007, Pages 338-344

  Schimke, Katrin ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MURAGLITAZAR; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; REGLITAZAR; RIVOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRY EYE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERURICEMIA; IN VITRO SELECTION; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEUKEMIA; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPTIMAL DRUG DOSE; PANCREAS ISLET BETA CELL; PANCREATITIS; PATENT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS, PHASE III; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; THIAZOLIDINEDIONES;

EID: 34147131103     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. 312329 Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker diabetic fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G BR J PHARMACOL 1998 125 8 1708-1714
2. 312590 A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA J BIOL CHEM 1998 273 49 32679-32684
3. 325238 Warner-Lambert reaffirms 30% EPS growth in 1999 and expects to achieve 20% EPS growth in 2000. Warner-Lambert Co PRESS RELEASE 1999 May 18
4. 337999 Drug development pipeline: Gemfibrozil, azelnidipine, CS-834, CS-940, MM-801, CS-891, CS-891B, CS-615, CS-747, CS-682, CS-780, CS-011, cadrofloxican, oxybutynin transdermal, TheraTech. Sankyo Co Ltd COMPANY COMMUNICATION 1999 August 25
5. 365323 The development of overt diabetes in young Zucker diabetic fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Pickavance L, Widdowson PS, King P, Ishii S, Tanaka H, Williams G BR J PHARMACOL 1998 125 4 767-770
6. 369576 Antidiabetic characterization of CS-011: A new thiazolidinedione with potent insulin-sensitizing activity. Araki K, Yachi M, Hagisawa Y, Tanaka N, Isobe A, Sakakibara S, Oshumi J, Tsuruta F, Izumi T, Fujita T, Fujiwara T et al DIABETES 2000 49 1 Abs 425-P
7. 369714 The antidiabetic effects of CI-1037/CS011, a new thiazolidinedione. Pulaski JT, Davis JA, Yuille K, Johnson JH DIABETES 2000 49 1 Abs 496-P
8. 370497 American Diabetes Association 60th Scientific Sessions San Antonio, TX, USA. Worker C IDDB MEETING REPORT 2000 June 9-13
9. 498905 Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker diabetic fatty rat. Pickavance LC, Widdowson PS, Foster JR, Williams G, Wilding JP INT J EXP PATHOL 2003 84 2 83-89
10. 411100 A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE et al PROC NATL ACAD SCI USA 2001 98 9 5306-5311
11. 426168 Fatty acids, eicosanoids, and hypolipideamic agents identified as ligands or peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W MOL ENDOCRINOL 1997 11 6 779-791
12. 466412 JT to terminate the clinical development of JTT-501. Japan Tobacco Inc PRESS RELEASE 2002 October 07
13. 579218 The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Ferre P DIABETES 2004 53 Suppl 1 S43-50
14. 594833 Perlegen licenses Mitsubishi's diabetes drug. Perlegen Sciences Inc PRESS RELEASE 2005 April 13
15. 595948 Overview of pipeline projects (as of November 2004). Mitsubishi Pharma Corp COMPANY WORLD WIDE WEB SITE 2004 November 04
16. 622625 Peroxisome proliferator-activated receptor (PPAR)-α: A pharmacological target with a promising future. Van Raalte DH, Li M, Pritchard HP, Wasan KM PHARMACEUTICAL RESEARCH 2004 21 9 1531-1538
17. 659999 Daiichi Sankyo Inc company website. Daiichi Sankyo Inc COMPANY WORLD WIDE WEB SITE 2004 April 03
18. 672647 The effects of rivoglitazone (PPARγ agonist) on adiponectin in healthy subjects. Triscari J, Dmuchowski C DIABETES 2006 55 6 Suppl 1 570-P
19. 672733 Glucose levels in type 2 diabetics treated for 6 weeks with rivoglitazone HCl (CS-011). Tsicari J, Dmuchowski C, Isaacsohn J DIABETES 2006 55 6 Suppl 1 571-P
20. 674933 Pharmacological characterization of rivoglitazone and its enantiomers in vitro and in vivo. Ohsumi J, Kanda S, Matsui Y, Ogata T, Tsuruta F, Hanzawa H, Izumi T DIABETES 2006 55 6 1 2093-PO
21. 676138 Daiichi Sankyo group research & development pipeline. Daiichi Sankyo Co Ltd COMPANY WORLD WIDE WEB SITE 2006 March 31
22. 734760 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J et al LANCET 2006 368 9541 1096-1105
23. 756003 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, Colleen O'Neill MC, Zinman B et al N ENGL J MED 2006 355 23 2427-2443
24. 756488 NCT00143520: A randomized, double-blind, double-dummy, placebo-controlled, 26-week, dose-response study of rivoglitazone HCl (CS-011) with active comparator (pioglitazone HCl) in subjects with type 2 diabetes. INTERNET SITE 2007 http://www.clinicaltrials.gov
25. 760147 Review: Peroxisome proliferator-activated receptor-γ and its role in the development and treatment of diabetes. Leff T, Matthews ST, Camp HS EXP DIABESITY RES 2004 5 2 99-109
26. 760251 Therapeutic roles of peroxisome proliferator-activated receptor agonists. Staels B, Fruchart J-C DIABETES 2005 54 8 2460-2470
27. 761117 Oral antidiabetic agents. Krentz AJ, Bailey CJ DRUGS 2005 65 3 385-411
28. 761335 Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome-activated receptors α and δ. Forman BM, Chen J, Evans RM PROC NATL ACAD SCI USA 1997 94 9 4312-4317
29. 761342 Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ MOL CELL BIOL 2000 20 14 5119-5128
30. 761354 Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ocha C, Tan S, Berkowitz K, Hodis H, Azen P DIABETES 2002 51 9 2796-2803
31. 761590 Thiazolidinediones. Yki-Jarvinen H N ENGL J MED 2004 351 11 1106-1118
32. 761593 Effectiveness and side effects of thiazolidinediones for type 2 diabetes: Real-life experience from a tertiary hospital. Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG MED J AUST 2004 181 10 536-539
33. 761594 Secondary prevention of macorvascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone clinical trial in macrovascular events): A randomized controlled trial. Dormady JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E et al LANCET 2005 366 9493 1279-1289
34. 761596 Hepatotoxicity with thiazolidinediones - is it a class effect? Scheen AJ DRUGS SAFETY 2001 24 12 873-888
35. 761597 Metabolic and non-metabolic factors determining troglitazone hepatoxicity: A review. Masubuchi Y DRUG METAB PHARMACOKINET 2006 21 5 347-356
36. 761598 Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Nissen SE, Wolski K, Topol EJ J AM MED ASSOC 2005 294 20 2581-2586
37. 761881 Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB BIOMARKERS 2005 10 4 295-309
38. 761889 Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR α/γ agonist: Evidence for urolithiasis as the inciting event in the mode of action. Dominick MA, White MR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, Cano M, Tannehill-Gregg S, Moehlenkamp JD, Waites CR, Schilling BE TOXICOL PATHOL 2006 34 7 903-920
39. 765760 Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPARγ agonists on rat primary hepatocytes and human HepG2 cells. Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP MOL DIVERS 2006 10 3 349-360
40. 765765 Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J CLIN THER 2002 24 3 378-396
41. 765766 A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Khan MA, St Peter JV, Xue JL DIABETES CARE 2002 25 4 708-711
42. 765769 A metaanalysis comparing the effects of thiazolidinediones on cardiovascular risk factors. Chiquette E, Ramirez G, Defromzo R ARCH INT MED 2004 164 19 2097-2104
43. 766337 β-Cell preservation with thiazolidinediones. Campbell IW, Mariz S DIABETES RES CLIN PRACT 2006 doi:10.1016/j.diabres.2006.08. 015